KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Novartis Ag (NVS) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Novartis Ag (NVS) over the last 17 years, with Q4 2025 value amounting to $3.6 billion.

  • Novartis Ag's Cost of Revenue rose 863.42% to $3.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $13.7 billion, marking a year-over-year increase of 679.82%. This contributed to the annual value of $13.7 billion for FY2025, which is 679.82% up from last year.
  • Latest data reveals that Novartis Ag reported Cost of Revenue of $3.6 billion as of Q4 2025, which was up 863.42% from $3.5 billion recorded in Q3 2025.
  • In the past 5 years, Novartis Ag's Cost of Revenue ranged from a high of $4.0 billion in Q1 2021 and a low of $2.9 billion during Q3 2022
  • For the 5-year period, Novartis Ag's Cost of Revenue averaged around $3.4 billion, with its median value being $3.3 billion (2024).
  • In the last 5 years, Novartis Ag's Cost of Revenue soared by 1414.41% in 2021 and then crashed by 2701.88% in 2022.
  • Over the past 5 years, Novartis Ag's Cost of Revenue (Quarter) stood at $4.0 billion in 2021, then fell by 23.52% to $3.0 billion in 2022, then decreased by 0.62% to $3.0 billion in 2023, then rose by 9.99% to $3.3 billion in 2024, then grew by 8.63% to $3.6 billion in 2025.
  • Its last three reported values are $3.6 billion in Q4 2025, $3.5 billion for Q3 2025, and $3.3 billion during Q2 2025.